Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure

Kristine R. Crews, Peggy S. Wimmer, Joanna Laizure, Scott Howard, Raul C. Ribeiro, Bassem I. Razzouk

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

The clearance of 2-chlorodeoxyadenosine (2-CdA) in patients with renal insufficiency has not been characterized previously. The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA. 2-CdA (9 mg/m 2 per day) was infused over 30 minutes daily for 5 days. Plasma and dialysate concentrations of 2-CdA were measured by high-performance liquid chromatography. The rate of this patient's 2-CdA clearance was lower than the rates reported for children with normal renal function. The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m 2 for the first 3 days of 2-CdA therapy. He did not experience untoward hematologic toxicity. Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction. More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment.

Original languageEnglish (US)
Pages (from-to)677-680
Number of pages4
JournalJournal of Pediatric Hematology/Oncology
Volume24
Issue number8
DOIs
StatePublished - Nov 1 2002

Fingerprint

Cladribine
Hemofiltration
Acute Kidney Injury
Renal Dialysis
Pharmacokinetics
Renal Insufficiency
Leukemia, Monocytic, Acute
Kidney
Dialysis Solutions
Cytarabine
High Pressure Liquid Chromatography
Exercise

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Hematology

Cite this

Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure. / Crews, Kristine R.; Wimmer, Peggy S.; Laizure, Joanna; Howard, Scott; Ribeiro, Raul C.; Razzouk, Bassem I.

In: Journal of Pediatric Hematology/Oncology, Vol. 24, No. 8, 01.11.2002, p. 677-680.

Research output: Contribution to journalArticle

@article{8ca26cf2ee3842e781f2b4b29737fd8d,
title = "Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure",
abstract = "The clearance of 2-chlorodeoxyadenosine (2-CdA) in patients with renal insufficiency has not been characterized previously. The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA. 2-CdA (9 mg/m 2 per day) was infused over 30 minutes daily for 5 days. Plasma and dialysate concentrations of 2-CdA were measured by high-performance liquid chromatography. The rate of this patient's 2-CdA clearance was lower than the rates reported for children with normal renal function. The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m 2 for the first 3 days of 2-CdA therapy. He did not experience untoward hematologic toxicity. Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction. More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment.",
author = "Crews, {Kristine R.} and Wimmer, {Peggy S.} and Joanna Laizure and Scott Howard and Ribeiro, {Raul C.} and Razzouk, {Bassem I.}",
year = "2002",
month = "11",
day = "1",
doi = "10.1097/00043426-200211000-00016",
language = "English (US)",
volume = "24",
pages = "677--680",
journal = "Journal of Pediatric Hematology/Oncology",
issn = "1077-4114",
publisher = "Lippincott Williams and Wilkins",
number = "8",

}

TY - JOUR

T1 - Pharmacokinetics of 2-chlorodeoxyadenosine in a child undergoing hemofiltration and hemodialysis for acute renal failure

AU - Crews, Kristine R.

AU - Wimmer, Peggy S.

AU - Laizure, Joanna

AU - Howard, Scott

AU - Ribeiro, Raul C.

AU - Razzouk, Bassem I.

PY - 2002/11/1

Y1 - 2002/11/1

N2 - The clearance of 2-chlorodeoxyadenosine (2-CdA) in patients with renal insufficiency has not been characterized previously. The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA. 2-CdA (9 mg/m 2 per day) was infused over 30 minutes daily for 5 days. Plasma and dialysate concentrations of 2-CdA were measured by high-performance liquid chromatography. The rate of this patient's 2-CdA clearance was lower than the rates reported for children with normal renal function. The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m 2 for the first 3 days of 2-CdA therapy. He did not experience untoward hematologic toxicity. Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction. More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment.

AB - The clearance of 2-chlorodeoxyadenosine (2-CdA) in patients with renal insufficiency has not been characterized previously. The authors describe the clinical course and the pharmacokinetics of 2-CdA in a child with acute monoblastic leukemia who experienced acute renal failure during treatment with cytarabine and 2-CdA. 2-CdA (9 mg/m 2 per day) was infused over 30 minutes daily for 5 days. Plasma and dialysate concentrations of 2-CdA were measured by high-performance liquid chromatography. The rate of this patient's 2-CdA clearance was lower than the rates reported for children with normal renal function. The average clearance rate, reflecting systemic clearance and clearance by continuous venovenous hemofiltration and hemodialysis, was 12.4 L/hour per m 2 for the first 3 days of 2-CdA therapy. He did not experience untoward hematologic toxicity. Because high 2-CdA plasma concentrations were observed in this patient, clinicians are advised to exercise caution when using this drug in patients with renal dysfunction. More experience in the administration of 2-CdA to patients with renal insufficiency will be necessary to determine the need for dosage adjustment.

UR - http://www.scopus.com/inward/record.url?scp=0036843559&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0036843559&partnerID=8YFLogxK

U2 - 10.1097/00043426-200211000-00016

DO - 10.1097/00043426-200211000-00016

M3 - Article

VL - 24

SP - 677

EP - 680

JO - Journal of Pediatric Hematology/Oncology

JF - Journal of Pediatric Hematology/Oncology

SN - 1077-4114

IS - 8

ER -